Branched Chain Amino Acid Transaminase (BCAT) is a key enzyme regulating the initial catabolism of branched-chain amino acids (BCAAs: leucine, isoleucine, and valine). It catalyzes the first, reversible transamination step that converts BCAAs into their corresponding α-keto acids (BCKAs).
There are two isoforms of BCAT: the cytosolic form (BCATc or BCAT1) and the mitochondrial form (BCATm or BCAT2). BCAT1 is mainly expressed in the brain and immune cells (such as activated T lymphocytes and macrophages), while BCAT2 is widely expressed in tissues such as skeletal muscle, kidney, pancreas, stomach, and colon. Unlike most amino acids, the initial site of BCAA catabolism is skeletal muscle rather than the liver, due to the low hepatic BCAT activity.
The primary functions of BCAT include regulating protein synthesis (via activation of the mTOR pathway), maintaining glucose homeostasis, participating in neurotransmitter synthesis, modulating immune responses, and contributing to energy metabolism. Leucine, in particular, serves as a potent metabolic signal that directly or indirectly activates the mTORC1 pathway, thereby affecting cell growth, autophagy, and insulin signaling.
Dysregulation of BCAT is closely associated with various diseases. Congenital defects in BCAT can cause maple syrup urine disease (MSUD). In addition, BCAT expression and activity are often altered in conditions such as type 1 and type 2 diabetes, obesity, and insulin resistance, leading to abnormal BCAA levels and contributing to lipid accumulation and metabolic disturbances. Moreover, BCAT1 is upregulated in multiple cancer types, where it contributes to metabolic reprogramming and promotes tumor growth and invasiveness. Altered BCAT expression is also implicated in Alzheimer’s disease, heart failure, and hepatic and renal disorders.
Thus, BCAT is not only a critical node in BCAA metabolism but is also closely involved in the development and progression of many chronic diseases, making its metabolic regulatory mechanisms an important subject of study[1][2].
Sodium α-ketoisocaproate(Sodium 4-methyl-2-oxopentanoate)是一种胰岛素促分泌剂,可在 BCAT 和 BCATm 的催化下发生转氨基反应生成 α-酮戊二酸和亮氨酸,还能结合 SUR1 位点以抑制 KATP 通道活性而不直接影响 Kir6.2 亚基,并调控 Ca2+ 内流,从而在胰岛以及 BCATm 表达充足的完整小鼠胰腺中发挥促胰岛素活性,可用于 2 型糖尿病的相关研究。
© 2026 MolStrong. 保留所有权利。粤ICP备2023004355号
可通过CAS号进行批量搜索,一行一个CAS号